New Insights into IL-12-mediated Tumor Suppression

Overview

Journal Cell Death Differ

Specialty Cell Biology

Date 2014 Sep 6

PMID 25190142

Citations 255

Authors

S Tugues

S H Burkhard

I Ohs

M Vrohlings

K Nussbaum

J Vom Berg

P Kulig

B Becher

Affiliations

Soon will be listed here.

Abstract

During the past two decades, interleukin-12 (IL-12) has emerged as one of the most potent cytokines in mediating antitumor activity in a variety of preclinical models. Through pleiotropic effects on different immune cells that form the tumor microenvironment, IL-12 establishes a link between innate and adaptive immunity that involves different immune effector cells and cytokines depending on the type of tumor or the affected tissue. The robust antitumor response exerted by IL-12, however, has not yet been successfully translated into the clinics. The majority of clinical trials involving treatment with IL-12 failed to show sustained antitumor responses and were associated to toxic side effects. Here we discuss the therapeutic effects of IL-12 from preclinical to clinical studies, and will highlight promising strategies to take advantage of the antitumor activity of IL-12 while limiting adverse effects.

Citing Articles

Improving IL12 immunotherapy in glioblastoma by targeting the long noncoding RNA INCR1.

Saini S, Gadet J, Freeman G, Chiocca E, Mineo M J Neurooncol. 2025; .

PMID: 40035950 DOI: 10.1007/s11060-025-04978-2.

Synthetic short mRNA prevents metastasis via innate-adaptive immunity.

Hayashi H, Seki S, Tomita T, Kato M, Ashihara N, Chano T Nat Commun. 2025; 16(1):1925.

PMID: 40000682 PMC: 11862117. DOI: 10.1038/s41467-025-57123-y.

Emerging role of bile acids in colorectal liver metastasis: From molecular mechanism to clinical significance (Review).

Li Z, Deng L, Cheng M, Ye X, Yang N, Fan Z Int J Oncol. 2025; 66(3).

PMID: 39981904 PMC: 11844338. DOI: 10.3892/ijo.2025.5730.

The IL-23/Th17 pathway inhibitors in the treatment of psoriasis and the risk of skin malignancies: a review.

Krzysztofik M, Brzewski P, Kulbat A, Masajada M, Richter K, Wysocki W Postepy Dermatol Alergol. 2025; 41(6):552-559.

PMID: 39877117 PMC: 11770571. DOI: 10.5114/ada.2024.143428.

IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy.

Jiang H, Limsuwannarot S, Kulhanek K, Pal A, Rysavy L, Su L bioRxiv. 2025; .

PMID: 39868284 PMC: 11760723. DOI: 10.1101/2025.01.15.633105.

References

Triozzi P, Allen K, Carlisle R, Craig M, LoBuglio A, Conry R . Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res. 2005; 11(11):4168-75. DOI: 10.1158/1078-0432.CCR-04-2283. View

Teng M, Andrews D, McLaughlin N, Von Scheidt B, Ngiow S, Moller A . IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci U S A. 2010; 107(18):8328-33. PMC: 2889517. DOI: 10.1073/pnas.1003251107. View

Bianchi R, Grohmann U, Vacca C, Belladonna M, Fioretti M, Puccetti P . Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation. J Immunol. 1999; 163(5):2517-21. View

Furumoto K, Arii S, Yamasaki S, Mizumoto M, Mori A, Inoue N . Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int J Cancer. 2000; 87(5):665-72. View

Zitvogel L, Lotze M . Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application. Res Immunol. 1995; 146(7-8):628-38. DOI: 10.1016/0923-2494(96)83041-0. View

Bekaii-Saab T, Roda J, Guenterberg K, Ramaswamy B, Young D, Ferketich A . A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther. 2009; 8(11):2983-91. PMC: 2996611. DOI: 10.1158/1535-7163.MCT-09-0820. View

Pflanz S, Timans J, Cheung J, Rosales R, Kanzler H, Gilbert J . IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002; 16(6):779-90. DOI: 10.1016/s1074-7613(02)00324-2. View

Schulz O, Edwards A, Schito M, Aliberti J, Manickasingham S, Sher A . CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity. 2000; 13(4):453-62. DOI: 10.1016/s1074-7613(00)00045-5. View

Airoldi I, Di Carlo E, Cocco C, Sorrentino C, Fais F, Cilli M . Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood. 2005; 106(12):3846-53. DOI: 10.1182/blood-2005-05-2034. View

10.

Norton J, Li M, Lee N, Tsung K . Inhibition of host signal transducer and activator of transcription factor 6 results in cure with cyclophosphamide and interleukin 12 immunotherapy. Ann Surg Oncol. 2005; 13(1):118-24. DOI: 10.1245/ASO.2006.03.514. View

11.

Chang C, Chen Y, Huang K, Cheng H, Chan S, Tai K . Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology. 2007; 45(3):746-54. DOI: 10.1002/hep.21560. View

12.

Sgadari C, Angiolillo A, Tosato G . Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 1996; 87(9):3877-82. View

13.

Babik J, Adams E, Tone Y, Fairchild P, Tone M, Waldmann H . Expression of murine IL-12 is regulated by translational control of the p35 subunit. J Immunol. 1999; 162(7):4069-78. View

14.

Rogge L, Papi A, Presky D, Biffi M, Minetti L, Miotto D . Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. J Immunol. 1999; 162(7):3926-32. View

15.

Salcedo T, Azzoni L, Wolf S, Perussia B . Modulation of perforin and granzyme messenger RNA expression in human natural killer cells. J Immunol. 1993; 151(5):2511-20. View

16.

Seo S, Kim K, Park S, Suh Y, Kim S, Jeun S . The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. 2011; 18(5):488-95. PMC: 3125103. DOI: 10.1038/gt.2010.170. View

17.

Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View

18.

Jahn T, Zuther M, Friedrichs B, Heuser C, Guhlke S, Abken H . An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack. PLoS One. 2012; 7(9):e44482. PMC: 3445545. DOI: 10.1371/journal.pone.0044482. View

19.

Sabel M, Su G, Griffith K, Chang A . Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat. 2009; 122(2):325-36. DOI: 10.1007/s10549-009-0570-3. View

20.

Langowski J, Zhang X, Wu L, Mattson J, Chen T, Smith K . IL-23 promotes tumour incidence and growth. Nature. 2006; 442(7101):461-5. DOI: 10.1038/nature04808. View